Skip to content
OpenCapital
Get started

Ocular Therapeutix OCUL Increase Decrease In Operating Lease Assets

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.16B+58.2%

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Reported directly by Ocular Therapeutix in its filing.

Tagged under the XBRL concept ocul:IncreaseDecreaseInOperatingLeaseAssets.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Ocular Therapeutix's increase decrease in operating lease assets?
Ocular Therapeutix (OCUL) reported increase decrease in operating lease assets of $1.86M in Q1 2026.
How has Ocular Therapeutix's increase decrease in operating lease assets changed year-over-year?
Ocular Therapeutix's increase decrease in operating lease assets increased by 1687.2% year-over-year, from -$117K to $1.86M.
What is the long-term trend for Ocular Therapeutix's increase decrease in operating lease assets?
Over 3 years (2021 to 2025), Ocular Therapeutix's increase decrease in operating lease assets has grown at a 11.7% compound annual growth rate (CAGR), from -$977K to -$1.36M.